Percutaneous management of pyogenic spondylodiscitis using absorbable antibiotic carrier (STIMULAN®): preliminary results from a single-center study.

Authors

Matteo Bellini, Joshua Adam Hirsch, Stefano Marcia, Ernesto Piane, Margherita Di Stefano, Vittoria Balletta, Marzio Formisano, Chiara Zini

Published in

Neuroradiology. Jun 14, 2025. Epub Jun 14, 2025.

Abstract

This study evaluates the feasibility of using a fully resorbable antibiotic carrier (STIMULAN®, Rapid Cure, Biocomposites Ltd, UK) for the targeted treatment of spondylodiscitis (SD) through percutaneous injection directly into the infection site.
Between 2022 and 2024, 13 patients diagnosed with SD underwent percutaneous osteo-discal biopsy followed by intradiscal and intravertebral injection of tailored antibiotic-loaded calcium sulfate paste. Clinical assessments (VAS), laboratory markers (CRP and leukocyte counts), and MRI imaging were used to monitor outcomes up to 12 months.
The procedure achieved 100% technical success with no major complications. All patients showed significant symptom relief, with VAS scores decreasing from 8.2 at baseline to 3.5 at 12 months. Inflammatory markers improved consistently, particularly CRP, which dropped from 7.35 to 0.23 (p ≈ 0.00005).
These findings suggest that STIMULAN® enables safe, effective local antibiotic delivery in SD, with meaningful clinical and biomarker improvements. Nonetheless, larger multicenter studies are needed to validate these preliminary results and assess long-term efficacy.

PMID:
40515821
Bibliographic data and abstract were imported from PubMed on 15 Jun 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.